Evidence map›Paper›PMID 33890628›Full record

Observational studyRheumatology (Oxford, England)2022

The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use.

Rugina I Neuman, Hieronymus T W Smeele, A H Jan Danser, Radboud J E M Dolhain, Willy Visser

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rugina I NeumanDepartment of Internal Medicine; Division of Pharmacology and Vascular Medicine.
Hieronymus T W SmeeleDepartment of Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
A H Jan DanserDepartment of Internal Medicine; Division of Pharmacology and Vascular Medicine.
Radboud J E M DolhainDepartment of Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
Willy VisserDepartment of Internal Medicine; Division of Pharmacology and Vascular Medicine.
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAn elevated sFlt-1/PlGF ratio has been validated as a significant predictor of preeclampsia, but has not been established in women with RA. We explored whether the sFlt-1/PlGFratio could be altered due to disease activity in RA, and could be applied in this population to predict preeclampsia. Since SSZ has been suggested to improve the angiogenic imbalance in preeclampsia, we also aimed to examine whether SSZ could affect sFlt-1 or PlGF levels.

methodsMaking use of a nationwide, observational, prospective cohort study on pregnant women with RA, sFlt-1 and PlGF were measured in the third trimester. A total of 221 women, aged 21-42 years, were included, with a median gestational age of 30 + 3 weeks.

resultsNo differences in sFlt-1 or PlGF were observed between women with high, intermediate or low disease activity (P = 0.07 and P = 0.41), whereas sFlt-1 and PlGF did not correlate with DAS28-CRP score (r = -0.01 and r = -0.05, respectively). Four (2%) women with a sFlt-1/PlGF ratio ≤38 developed preeclampsia in comparison to three (43%) women with a ratio > 38, corresponding to a negative predictive value of 98.1%. SSZ users (n = 57) did not show altered levels of sFlt-1 or PlGF in comparison to non-SSZ users (n = 164, P = 0.91 and P = 0.11).

conclusionOur study shows that in pregnant women with RA, the sFlt-1/PlGF ratio is not altered due to disease activity and a cut-off ≤38 can be used to exclude preeclampsia. Additionally, SSZ use did not affect sFlt-1 or PlGF levels in this population.

Indexed as

AdultAntirheumatic AgentsArthritis, RheumatoidBiomarkersFemaleHumansMembrane ProteinsPre-EclampsiaPregnancyPregnancy ComplicationsPregnancy Trimester, ThirdProspective StudiesSulfasalazineVascular Endothelial Growth Factor Receptor-1Young AdultAntirheumatic AgentsBiomarkersFLT1 protein, humanMembrane ProteinsPIGF protein, humanSulfasalazineVascular Endothelial Growth Factor Receptor-1angiogenesisPlGFpredictionpreeclampsiarheumatoid arthritissFlt-1

Identifiers

PMID33890628
OpenAlexW3155788819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.